Verapamil is a Non-Dihydropyridine Calcium Channel Blocker and is Generally Contraindicated in Left-to-Right Shunts
Verapamil should NOT be used in patients with left-to-right cardiac shunts due to its negative inotropic effects and risk of worsening heart failure. 1
Drug Classification
Verapamil is a non-dihydropyridine calcium channel blocker (calcium ion antagonist) that inhibits calcium influx through slow channels in vascular smooth muscle and cardiac cells 2, 3. It acts primarily on:
- AV nodal tissue - prolongs effective refractory period and slows AV conduction 2
- Arterial smooth muscle - causes peripheral and coronary vasodilation 3
- Myocardial contractility - exerts negative inotropic effects 3
The drug is FDA-approved for supraventricular tachyarrhythmias, vasospastic angina, and hypertension 3, 4.
Why Verapamil is Contraindicated in Left-to-Right Shunts
Negative Inotropic Effects Predominate
In left-to-right shunts (such as ventricular septal defects, atrial septal defects, or patent ductus arteriosus), the heart already faces volume overload and often impaired ventricular function. Verapamil's negative inotropic action can precipitate or worsen heart failure in this setting 1.
The 1995 ACC/AHA Heart Failure Guidelines explicitly state that vasodilators are generally contraindicated in patients with Eisenmenger's syndrome (the end-stage of untreated left-to-right shunts) unless the shunt has been surgically corrected 1. While verapamil causes systemic vasodilation, with relatively fixed pulmonary vascular resistance, it can increase right-to-left shunting and decrease systemic arterial oxygen saturation 1.
Unpredictable Hemodynamic Effects
In left-to-right shunts where right and left ventricular systolic pressures are equal, the shunt magnitude depends on the balance between pulmonary and systemic vascular resistance 1. Because verapamil lacks differential effects on pulmonary versus systemic circulation, outcomes are unpredictable - some patients may worsen with increased shunt flow and pulmonary congestion 1.
Specific Contraindications from FDA Labeling
Verapamil is absolutely contraindicated in 3:
- Severe left ventricular dysfunction
- Hypotension (systolic <90 mmHg) or cardiogenic shock
- Heart failure with reduced ejection fraction
Because of negative inotropic effects, non-dihydropyridine calcium channel antagonists (including verapamil) may further decompensate patients with left ventricular systolic dysfunction and symptomatic heart failure 5.
Clinical Context: When Verapamil IS Appropriate
Verapamil has well-established efficacy in:
- Supraventricular tachycardias - particularly AVNRT and AVRT 2, 5
- Verapamil-sensitive idiopathic left ventricular tachycardia (interfascicular reentrant VT) 6
- Rate control in atrial fibrillation/flutter WITHOUT preexcitation 5
However, even in these arrhythmias, verapamil should NOT be given to patients with impaired ventricular function or heart failure 2.
Critical Pitfalls to Avoid
Never use verapamil in wide-complex tachycardias of unknown etiology - it can cause profound hypotension, shock, or precipitate ventricular fibrillation 5
Avoid in pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome) - it may accelerate ventricular rate and cause ventricular fibrillation 5, 7, 3
Do not combine with beta-blockers in patients with compromised ventricular function - additive negative inotropic effects 2
In pediatric left-to-right shunts, the controversy surrounds digoxin and ACE inhibitors, NOT verapamil - verapamil is not recommended for this indication 1